Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina

Table 2 Type and risks of clinical events included in the model (reported per 100 patient/years)

Events	Apixaban	Warfarin	Source
Ischemic stroke risk by CHADS2			[15]
Mean	0,962	1,064
CHADS₂ score 0	0,521	0,458
CHADS₂ score 1	0,521	0,458
CHADS₂ score 2	0,950	0,934
CHADS₂ score 3	1,534	1,944
CHADS₂ score 4	1,534	1,944
CHADS₂ score 5	1,534	1,944
CHADS₂ score 6	1,534	1,944
Systemic embolism	0.090	0.100	[12]
Hemorrhagic stroke and Intracranial Hemorrhage	0.330	0.800	[12]
Other major bleeding	1.790	2.270	[12]
Clinically Relevant Non-Major Bleeding	2.083	2.995	[15]
Myocardial Infarction	0,530	0,610	[12]
Other hospitalizations due to cardiovascular disease	10.460	10.460	[15]
Recurrent ischemic stroke	4.103	4.103	[43]
Recurrent hemorrhagic stroke	3.00	3.00	[43]

ISSN: 2191-1991